SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Ivermectin (3.5%) Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Kilsheelan
   Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4 : H302: Harmful if swallowed.
   Specific target organ toxicity - single exposure, Category 2 : H371: May cause damage to organs.
   Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   Short-term (acute) aquatic hazard, Category 1 : H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Warning
   Hazard statements : H302 Harmful if swallowed.
   H371 May cause damage to organs.
   H373 May cause damage to organs through prolonged or
repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:

**Prevention:**
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.

**Response:**
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Ivermectin

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 1.42 %

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7 274-536-0</td>
<td>Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system)</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>
## Ivermectin (3.5%) Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>27.08.2021</td>
<td>4707608-00006</td>
<td>09.04.2021</td>
<td>29.07.2019</td>
</tr>
</tbody>
</table>

### Aquatic Acute 1; H400
### Aquatic Chronic 1; H410

<table>
<thead>
<tr>
<th>M-Factor (Acute aquatic toxicity): 10,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>M-Factor (Chronic aquatic toxicity): 10,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2,6-Di-tert-butyl-p-cresol</th>
<th>128-37-0 204-881-4</th>
<th>Aquatic Acute 1; H400 Aquatic Chronic 1; H410</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt;= 0.25 - &lt; 1</td>
</tr>
</tbody>
</table>

M-Factor (Acute aquatic toxicity): 1
M-Factor (Chronic aquatic toxicity): 1

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

**General advice**: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled**: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

**In case of skin contact**: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

**In case of eye contact**: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

**If swallowed**: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Ivermectin (3.5%) Formulation

4.2 Most important symptoms and effects, both acute and delayed
Risks:
- Harmful if swallowed.
- May cause damage to organs.
- May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment:
- Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Metal oxides

5.3 Advice for firefighters
Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Do not breathe vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage: Keep in properly labelled containers. Store locked up. Store in
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin (3.5%) Formulation

Version 2.4  Revision Date: 27.08.2021  SDS Number: 4707608-00006  Date of last issue: 09.04.2021
Date of first issue: 29.07.2019

areas and containers  accordance with the particular national regulations.

Advice on common storage  :  Do not store with the following product types:
                         1. Strong oxidizing agents
                         2. Organic peroxides
                         3. Explosives
                         4. Gases

7.3 Specific end use(s)
Specific use(s)  :  No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>Ivermectin</td>
</tr>
</tbody>
</table>
   Further information: Skin

   Wipe limit 0.5 mg/100 cm²  Internal

| Aluminum tri-stearate | 637-12-7 | OELV - 8 hrs (TWA) | 10 mg/m3 | IE OEL |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | OELV - 8 hrs (TWA) | 2 mg/m3 | IE OEL |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>177.79 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>25.21 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>43.84 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>3.5 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Dermal</td>
<td>Long-term systemic effects</td>
<td>0.5 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>0.86 mg/m3</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Dermal</td>
<td>Long-term systemic effects</td>
<td>0.25 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>0.25 mg/kg bw/day</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin (3.5%) Formulation

Version 2.4  Revision Date: 27.08.2021  SDS Number: 4707608-00006  Date of last issue: 09.04.2021  Date of first issue: 29.07.2019

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Oral (Secondary Poisoning)</td>
<td>0.03 mg/kg food</td>
</tr>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>Fresh water</td>
<td>0.199 µg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>0.02 µg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.02 µg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>0.17 µg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>0.00996 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.00996 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.04769 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Oral (Secondary Poisoning)</td>
<td>8.33 mg/kg food</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Eye protection
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material
Chemical-resistant gloves

Remarks
Consider double gloving.

Skin and body protection
Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 14387

Filter type
Combined particulates and organic vapour type (A-P)
### Ivermectin (3.5%) Formulation

**SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>gel</td>
</tr>
<tr>
<td>Colour</td>
<td>off-white</td>
</tr>
<tr>
<td>Odour</td>
<td>characteristic</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>170 °C</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>237.2 °C</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>382 - 384 mPa.s (25 °C)</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>practically insoluble</td>
</tr>
<tr>
<td>Water solubility</td>
<td></td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>0.93 - 0.95</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle characteristics</td>
<td></td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>

#### 9.2 Other information
**SAFETY DATA SHEET**
according to Regulation (EC) No. 1907/2006

**Ivermectin (3.5%) Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>27.08.2021</td>
<td>4707608-00006</td>
<td>09.04.2021</td>
</tr>
</tbody>
</table>

Explosives: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Evaporation rate: No data available

Molecular weight: No data available

**SECTION 10: Stability and reactivity**

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

**SECTION 11: Toxicological information**

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**
Harmful if swallowed.

**Product:**

**Acute oral toxicity**
Acute toxicity estimate: 1,511 mg/kg
Method: Calculation method

**Acute dermal toxicity**
Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

**Components:**

**Ivermectin:**
Acute oral toxicity: LD50 (Rat): 50 mg/kg
Ivermectin (3.5%) Formulation

LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
   Exposure time: 1 h
   Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:
Acute oral toxicity: LD50 (Rat): > 6,000 mg/kg
   Method: OECD Test Guideline 401

Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
   Method: OECD Test Guideline 402
   Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Ivermectin:
Species: Rabbit
Result: No skin irritation

2,6-Di-tert-butyl-p-cresol:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ivermectin:
Species: Rabbit
Result: Mild eye irritation

2,6-Di-tert-butyl-p-cresol:
Species: Rabbit
Method: OECD Test Guideline 405
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Ivermectin:
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:
Test Type: Human repeat insult patch test (HRIPT)
Exposure routes: Skin contact
Species: Humans
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Ivermectin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

2,6-Di-tert-butyl-p-cresol:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative
Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Ivermectin:
Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:
Species: Rat
Application Route: Ingestion
Exposure time: 22 Months
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:
Ivermectin:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

2,6-Di-tert-butyl-p-cresol:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure
May cause damage to organs.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

2,6-Di-tert-butyl-p-cresol:
Assessment: No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

Repeated dose toxicity

Components:
Ivermectin:
Ivermectin (3.5%) Formulation

Species: Dog
NOAEL: 0.5 mg/kg
LOAEL: 1 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system
Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species: Monkey
NOAEL: 1.2 mg/kg
Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:
Species: Rat
NOAEL: 25 mg/kg
Application Route: Ingestion
Exposure time: 22 Months

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin (3.5%) Formulation

Version 2.4  Revision Date: 27.08.2021  SDS Number: 4707608-00006  Date of last issue: 09.04.2021  Date of first issue: 29.07.2019

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ivermectin:
Toxicity to fish: LC50 (Onchorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.00025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 10,000

M-Factor (Chronic aquatic toxicity): 10,000

2,6-Di-tert-butyl-p-cresol:
Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 0.57 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.48 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 1

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Ivermectin (3.5%) Formulation

Toxicity to microorganisms : EC50 : > 10,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.053 mg/l
Exposure time: 30 d
Species: Oryzias latipes (Japanese medaka)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.316 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic toxicity) : 1

12.2 Persistence and degradability

Components:
Ivermectin:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

2,6-Di-tert-butyl-p-cresol:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4.5 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:
Ivermectin:
Bioaccumulation : Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water : log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:
Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800
Partition coefficient: n-octanol/water : log Pow: 5.1

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Product:
Assessment : This substance/mixture contains no components considered
to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th>ADN</th>
<th>UN 3082</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>UN 3082</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3082</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3082</td>
</tr>
<tr>
<td>IATA</td>
<td>UN 3082</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin (3.5%) Formulation

Version 2.4  Revision Date: 27.08.2021  SDS Number: 4707608-00006  Date of last issue: 09.04.2021

Date of first issue: 29.07.2019

IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)

IATA: Environmentally hazardous substance, liquid, n.o.s. (Ivermectin)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards
SAFETY DATA SHEET
generated according to Regulation (EC) No. 1907/2006

Ivermectin (3.5%) Formulation

Version 2.4 Revision Date: 27.08.2021 SDS Number: 4707608-00006 Date of last issue: 09.04.2021 Date of first issue: 29.07.2019

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)
Conditions of restriction for the following entries should be considered:
Number on list 3

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer
Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)
Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals
Not applicable

REACH - List of substances subject to authorisation (Annex XIV)
Not applicable


| Other regulations: |
| Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable. |
| Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable. |

| Quantity 1 | Quantity 2 |
| 100 t | 200 t |
The components of this product are reported in the following inventories:

AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H300: Fatal if swallowed.
H311: Toxic in contact with skin.
H370: Causes damage to organs if swallowed.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
STOT RE: Specific target organ toxicity - repeated exposure
STOT SE: Specific target organ toxicity - single exposure
IE OEL: Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA): Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a
Ivermectin (3.5%) Formulation


Classification of the mixture:

- Acute Tox. 4: H302
- STOT SE 2: H371
- STOT RE 2: H373
- Aquatic Acute 1: H400
- Aquatic Chronic 1: H410

Classification procedure:

- Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.